IRWD
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Key Takeaway: Ironwood Pharmaceuticals presented a late-breaker session at Digestive Disease Week, emphasizing the potential benefits of once-weekly apraglutide for adults suffering from Short Bowel Syndrome with Intestinal Failure. The presentation aims to address the significant unmet medical needs within this patient demographic. The findings suggest promising outcomes that could enhance treatment options.
Price reaction · baseline $6.42 (2024-05-20 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
+5.6%
day 1
+1.1%
day 3 · peak
-7.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is apraglutide?
Apraglutide is a medication being studied for its potential benefits in treating Short Bowel Syndrome.
What condition does apraglutide target?
Apraglutide targets Short Bowel Syndrome with Intestinal Failure in adults.
When was the presentation at Digestive Disease Week?
The presentation took place during the Digestive Disease Week event.
What is the dosing schedule for apraglutide?
Apraglutide is proposed to be administered once weekly.